Literature DB >> 22657730

Population-based esophageal cancer survival after resection without neoadjuvant therapy: an update.

Martin Rutegård1, Konstantinos Charonis, Yunxia Lu, Pernilla Lagergren, Jesper Lagergren, Ioannis Rouvelas.   

Abstract

BACKGROUND: There are few population-based studies addressing the survival after resection for esophageal cancer. This study represents an update of a nationwide Swedish cohort initiated in 1987.
METHODS: Based on data from the Swedish Patient Register, Swedish Cancer Register, and histopathologic records, 1,008 patients who had undergone esophageal resection as the only treatment for esophageal cancer were identified between January 1, 1987 and December 31, 2005. These were followed until death or emigration through linkage to the Swedish Total Population Register until January 1, 2009. Tumor stage, location, and histology were assessed from histopathologic reports, and comorbidities were assessed from the Patient Register. Cox proportional hazards regression models were used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) regarding survival. The results were adjusted for age, sex, comorbidity, tumor stage, location, histology, surgical radicality, and hospital volume.
RESULTS: The proportion of patients surviving for 5 years increased from 19.7% in 1987-1991 to 30.7% in 1997-2000, but remained at 30.5% between 2001 and 2005. No difference in overall adjusted survival was found between the periods of 2001-2005 and 1997-2000 (adjusted HR, 0.89; 95% CI, 0.70-1.13). Thirty-day mortality decreased from 4.9% in 1997-2000 to 2.0% in 2001-2005, rendering an adjusted HR of 0.26 (95% CI, 0.08-0.87).
CONCLUSION: After adjusting for relevant prognostic factors, long-term population-based survival after resection for esophageal cancer was unchanged between 2001 and 2005 compared to 1997-2000, while the corresponding 30-day mortality improved.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22657730     DOI: 10.1016/j.surg.2012.03.025

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  17 in total

Review 1.  Perioperative therapy for esophageal cancer.

Authors:  Makoto Yamasaki; Hiroshi Miyata; Yasuhiro Miyazaki; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-07-29

Review 2.  Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer.

Authors:  Jing Liu; Jinbo Yue; Ligang Xing; Jinming Yu
Journal:  Front Med       Date:  2013-05-17       Impact factor: 4.592

3.  Influence of Treatment Caused Impairments on Anxiety and Depression in Patients with Cancer of the Esophagus or the Esophagogastric Junction.

Authors:  Thomas Kiefer; Dorothea Krahl; Carsten Hirt; Heinz Völler; Lorenz Völkel; Georg Daeschlein
Journal:  J Gastrointest Cancer       Date:  2020-03

4.  KISS-1, Mediated by Promoter Methylation, Suppresses Esophageal Squamous Cell Carcinoma Metastasis via MMP2/9/MAPK Axis.

Authors:  Houyu Duan; Xiang Ding; Hesheng Luo
Journal:  Dig Dis Sci       Date:  2022-01-07       Impact factor: 3.487

5.  Association of promoter methylation of RUNX3 gene with the development of esophageal cancer: a meta analysis.

Authors:  Yi Wang; Xiuguang Qin; Jieqing Wu; Bo Qi; Yipeng Tao; Wenju Wang; Fulei Liu; Hanchen Li; Baosheng Zhao
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

6.  Lymphadenectomy and risk of reoperation or mortality shortly after surgery for oesophageal cancer.

Authors:  Jesper Lagergren; Fredrik Mattsson; Andrew Davies; Mats Lindblad; Pernilla Lagergren
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

7.  Role of MLH1 methylation in esophageal cancer carcinogenesis and its clinical significance.

Authors:  Jinyun Li; Dong Ye; Lei Wang; Yingying Peng; Qun Li; Hongxia Deng; Chongchang Zhou
Journal:  Onco Targets Ther       Date:  2018-02-01       Impact factor: 4.147

8.  Meta-analysis shows clinically relevant and long-lasting deterioration in health-related quality of life after esophageal cancer surgery.

Authors:  M Jacobs; R C Macefield; R G Elbers; K Sitnikova; I J Korfage; E M A Smets; I Henselmans; M I van Berge Henegouwen; J C J M de Haes; J M Blazeby; M A G Sprangers
Journal:  Qual Life Res       Date:  2013-12-03       Impact factor: 4.147

9.  The feasibility of a randomized controlled trial of esophagectomy for esophageal cancer--the ROMIO (Randomized Oesophagectomy: Minimally Invasive or Open) study: protocol for a randomized controlled trial.

Authors:  Kerry N L Avery; Chris Metcalfe; Richard Berrisford; C Paul Barham; Jenny L Donovan; Jackie Elliott; Stephen J Falk; Rob Goldin; George Hanna; Andrew A Hollowood; Richard Krysztopik; Sian Noble; Grant Sanders; Christopher G Streets; Dan R Titcomb; Tim Wheatley; Jane M Blazeby
Journal:  Trials       Date:  2014-06-02       Impact factor: 2.279

10.  Early diagnostic potential of APC hypermethylation in esophageal cancer.

Authors:  Bujiang Wang; Haojun Song; Haizhong Jiang; Yangbo Fu; Xiaoyun Ding; Chongchang Zhou
Journal:  Cancer Manag Res       Date:  2018-02-01       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.